Literature DB >> 10088763

Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.

L Guillevin1, B Durand-Gasselin, R Cevallos, M Gayraud, F Lhote, P Callard, J Amouroux, P Casassus, B Jarrousse.   

Abstract

OBJECTIVE: To retrospectively analyze the clinical symptoms, laboratory findings, and outcomes in patients with microscopic polyangiitis (MPA) who were enrolled in various clinical trials conducted by the French Vasculitis Study Group.
METHODS: A cohort of 85 patients meeting the Chapel Hill criteria for MPA participated in the study. Seventy-one of them were included in prospective therapeutic trials. Eighty-one diagnoses were biopsy proven. In the other patients, diagnosis was based on clinical findings.
RESULTS: Forty-seven men and 38 women, with a mean +/- SD age of 56.8 +/- 14.6 years, met the criteria for MPA. Their main clinical symptoms were renal manifestations (78.8%), weight loss (72.9%), skin involvement (62.4%), fever (55.3%), mononeuritis multiplex (57.6%), arthralgias (50.6%), myalgias (48.2%), hypertension (34.1%), lung involvement (24.7%; alveolar hemorrhage 11.8%), and cardiac failure (17.6%). The mean +/- SD serum creatinine level before treatment was 2.59 +/- 2.96 mg/dl; 47 patients had renal insufficiency (serum creatinine > 1.36 mg/dl). Eight patients underwent dialysis at the time of diagnosis, and long-term dialysis was necessary for 10 patients. Antineutrophil cytoplasmic antibodies (ANCA) were present in 38 of 51 patients (74.5%), of whom 33 had a perinuclear staining pattern (pANCA) and 5 had a cytoplasmic pattern. Antibodies to proteinase 3 were present in 4 patients and antibodies to myeloperoxidase were detected in 31, as determined by enzyme-linked immunosorbent assay. Of the 30 patients who underwent renal and celiac angiography, 4 had microaneurysms. Of the 29 patients (34.1%) who had relapses, 8 died during or after the relapse. During followup, 28 of the 85 patients (32.9%) died. The mean +/- SD duration of followup of the group was 69.9 +/- 60.6 months. Deaths were less frequent when patients had been treated with steroids and immunosuppressive drugs (13 patients [24.1%]) than with steroids alone (15 patients [48.4%]) (P < 0.01). The 5-year survival rate was 74%.
CONCLUSION: This study demonstrated that MPA is a multisystemic disease in which renal symptoms are frequent, but the disease is also associated with general symptoms, arthritis, mononeuritis multiplex, and other manifestations that are also seen in various vasculitides. The rarity of abnormal angiogram findings and the high frequency of pANCA are characteristic of MPA. In most cases, the outcome is comparable with those of other systemic vasculitides, but relapses are frequent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088763     DOI: 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  134 in total

Review 1.  Perspective on future therapy of vasculitis.

Authors:  D T Boumpas; H D Kritikos; N G Daskalakis
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 3.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 4.  Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations.

Authors:  Laura B Hughes; S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

5.  [Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)].

Authors:  J U Holle; F Moosig; W L Gross
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

6.  Pulmonary aneurysms in microscopic polyangiitis.

Authors:  Vera Ortiz-Santamaria; Alejandro Olivé; Susana Holgado; Jordi Muchart
Journal:  Clin Rheumatol       Date:  2003-09-16       Impact factor: 2.980

Review 7.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

8.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

9.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.

Authors:  Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks
Journal:  Ann Rheum Dis       Date:  2015-11-30       Impact factor: 19.103

Review 10.  Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Haruki Koike; Gen Sobue
Journal:  Clin Exp Nephrol       Date:  2013-02-06       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.